BACKGROUND: Neoadjuvant therapy is commonly administered to patients with localized disease who have T3-4 esophageal disease as staged by endoscopic ultrasound (EUS). Previously, we noted that patients who present with dysphagia have a higher EUS T stage. We hypothesized that the presence of dysphagia is predictive of EUS T3-4 disease and that staging EUS could be forgone for esophageal cancer patients with dysphagia. METHODS: We performed a prospective, intent-to-treat, single-cohort study in which patients with potentially resectable esophageal cancer completed a standardized four-tier dysphagia score survey. EUS was performed as part of our standard evaluation. To determine whether the presence of dysphagia predicted EUS T3-4 disease, the dysphagia score was compared with EUS T stage. RESULTS: The study enrolled 114 consecutive patients between August 2012 and February 2014: 77% (88 of 114) received neoadjuvant therapy, 18% (20 of 114) did not, and 5% (6 of 114) pursued treatment elsewhere. In total, 70% (80 of 114) underwent esophagectomy; of these, 54% (61 of 114) had dysphagia and 46% (53 of 114) did not. Dysphagia scores were 66% (40 of 61) grade 1, 25% (15 of 61) grade 2, and 10% (6 of 61) grade 3 to 4. Among patients with dysphagia, 89% (54 of 61) had T3-4 disease by EUS; among those without dysphagia, only 53% (28 of 53) had T3-4 disease by EUS (p < 0.001). CONCLUSIONS: The presence of dysphagia in patients with esophageal cancer was highly predictive of T3-4 disease by EUS. On the basis of this finding, approximately 50% of patients currently undergoing staging EUS at our institution could potentially forgo EUS before neoadjuvant therapy. Patients without dysphagia, however, should still undergo EUS.
BACKGROUND: Neoadjuvant therapy is commonly administered to patients with localized disease who have T3-4 esophageal disease as staged by endoscopic ultrasound (EUS). Previously, we noted that patients who present with dysphagia have a higher EUS T stage. We hypothesized that the presence of dysphagia is predictive of EUS T3-4 disease and that staging EUS could be forgone for esophageal cancerpatients with dysphagia. METHODS: We performed a prospective, intent-to-treat, single-cohort study in which patients with potentially resectable esophageal cancer completed a standardized four-tier dysphagia score survey. EUS was performed as part of our standard evaluation. To determine whether the presence of dysphagia predicted EUS T3-4 disease, the dysphagia score was compared with EUS T stage. RESULTS: The study enrolled 114 consecutive patients between August 2012 and February 2014: 77% (88 of 114) received neoadjuvant therapy, 18% (20 of 114) did not, and 5% (6 of 114) pursued treatment elsewhere. In total, 70% (80 of 114) underwent esophagectomy; of these, 54% (61 of 114) had dysphagia and 46% (53 of 114) did not. Dysphagia scores were 66% (40 of 61) grade 1, 25% (15 of 61) grade 2, and 10% (6 of 61) grade 3 to 4. Among patients with dysphagia, 89% (54 of 61) had T3-4 disease by EUS; among those without dysphagia, only 53% (28 of 53) had T3-4 disease by EUS (p < 0.001). CONCLUSIONS: The presence of dysphagia in patients with esophageal cancer was highly predictive of T3-4 disease by EUS. On the basis of this finding, approximately 50% of patients currently undergoing staging EUS at our institution could potentially forgo EUS before neoadjuvant therapy. Patients without dysphagia, however, should still undergo EUS.
Authors: P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast Journal: N Engl J Med Date: 2012-05-31 Impact factor: 91.245
Authors: Traves D Crabtree; Wael N Yacoub; Varun Puri; Riad Azar; Jennifer Bell Zoole; G Alexander Patterson; A Sasha Krupnick; Daniel Kreisel; Bryan F Meyers Journal: Ann Thorac Surg Date: 2011-03-24 Impact factor: 4.330
Authors: Thomas W Rice; Eugene H Blackstone; David J Adelstein; Gregory Zuccaro; John J Vargo; John R Goldblum; Sudish C Murthy; Malcolm M DeCamp; Lisa A Rybicki Journal: J Thorac Cardiovasc Surg Date: 2003-05 Impact factor: 5.209
Authors: Christian G Peyre; Jeffrey A Hagen; Steven R DeMeester; Jan J B Van Lanschot; Arnulf Hölscher; Simon Law; Alberto Ruol; Ermanno Ancona; S Michael Griffin; Nasser K Altorki; Thomas W Rice; John Wong; Toni Lerut; Tom R DeMeester Journal: Ann Surg Date: 2008-12 Impact factor: 12.969
Authors: Andrew P Barbour; Nabil P Rizk; Hans Gerdes; Manjit S Bains; Valerie W Rusch; Murray F Brennan; Daniel G Coit Journal: J Am Coll Surg Date: 2007-07-20 Impact factor: 6.113
Authors: Tara R Semenkovich; Roheena Z Panni; Jessica L Hudson; Theodore Thomas; Leisha C Elmore; Su-Hsin Chang; Bryan F Meyers; Benjamin D Kozower; Varun Puri Journal: J Thorac Cardiovasc Surg Date: 2018-01-12 Impact factor: 5.209
Authors: Zuhair Ahmed; Jessie A Elliott; Sinead King; Claire L Donohoe; Narayanasamy Ravi; John V Reynolds Journal: World J Surg Date: 2017-02 Impact factor: 3.352
Authors: Zachary L Smith; Jason E Gonzaga; George B Haasler; Elizabeth M Gore; Kulwinder S Dua Journal: Dig Dis Sci Date: 2017-04-08 Impact factor: 3.199
Authors: Smita Sihag; Tamar Nobel; Meier Hsu; Sergio De La Torre; Kay See Tan; Yelena Y Janjigian; Geoffrey Y Ku; Laura H Tang; Abraham J Wu; Steven B Maron; Manjit S Bains; David R Jones; Daniela Molena Journal: Ann Surg Date: 2020-11-17 Impact factor: 12.969
Authors: Smita Sihag; Tamar Nobel; Meier Hsu; Kay See Tan; Rebecca Carr; Yelena Y Janjigian; Laura H Tang; Abraham J Wu; Matthew J Bott; James M Isbell; Manjit S Bains; David R Jones; Daniela Molena Journal: Ann Surg Date: 2020-11-17 Impact factor: 13.787
Authors: Yusuke Shimodaira; Rebecca S Slack; Kazuto Harada; Manoop S Bhutani; Elena Elimova; Gregg A Staerkel; Nour Sneige; Jeremy Erasmus; Hironori Shiozaki; Nikolaos Charalampakis; Venkatram Planjery; Dilsa Mizrak Kaya; Fatemeh G Amlashi; Mariela A Blum; Heath D Skinner; Bruce D Minsky; Dipen M Maru; Wayne L Hofstetter; Stephen G Swisher; Jeannette E Mares; Jane E Rogers; Quan D Lin; William A Ross; Brian Weston; Jeffrey H Lee; Jaffer A Ajani Journal: Oncotarget Date: 2017-05-23